Atara Biotherapeutics Inc. (ATRA) Raised to “Hold” at Zacks Investment Research
According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “
ATRA has been the subject of a number of other research reports. Goldman Sachs Group Inc. downgraded shares of Atara Biotherapeutics from a neutral rating to a sell rating and lowered their price target for the company from $23.00 to $16.00 in a report on Thursday, September 15th. Jefferies Group reaffirmed a buy rating and issued a $25.00 price target on shares of Atara Biotherapeutics in a report on Sunday, July 10th. Citigroup Inc. increased their price target on shares of Atara Biotherapeutics from $8.00 to $10.00 and gave the company a sell rating in a report on Friday, August 19th. Finally, JMP Securities reissued a buy rating on shares of Atara Biotherapeutics in a research report on Saturday, July 9th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $26.14.
Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 16.35 on Monday. The stock has a 50 day moving average price of $19.86 and a 200-day moving average price of $20.28. Atara Biotherapeutics has a 12 month low of $13.31 and a 12 month high of $40.80. The company’s market capitalization is $471.06 million.
Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Monday, August 8th. The company reported ($0.66) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.61) by $0.05. Analysts forecast that Atara Biotherapeutics will post ($2.85) EPS for the current year.
In other news, CEO Isaac E. Ciechanover sold 7,200 shares of the firm’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $19.36, for a total transaction of $139,392.00. Following the transaction, the chief executive officer now directly owns 229,136 shares of the company’s stock, valued at $4,436,072.96. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $20.87, for a total transaction of $250,440.00. Following the transaction, the chief executive officer now directly owns 406,578 shares in the company, valued at $8,485,282.86. The disclosure for this sale can be found here. Insiders own 16.10% of the company’s stock.
Institutional investors have recently modified their holdings of the company. A.R.T. Advisors LLC raised its position in shares of Atara Biotherapeutics by 79.6% in the first quarter. A.R.T. Advisors LLC now owns 63,941 shares of the company’s stock worth $1,216,000 after buying an additional 28,330 shares during the period. Bridger Management LLC bought a new position in shares of Atara Biotherapeutics during the first quarter worth approximately $14,072,000. California State Teachers Retirement System raised its position in shares of Atara Biotherapeutics by 35.3% in the second quarter. California State Teachers Retirement System now owns 48,704 shares of the company’s stock worth $1,096,000 after buying an additional 12,704 shares during the period. Bank of New York Mellon Corp raised its position in shares of Atara Biotherapeutics by 20.9% in the second quarter. Bank of New York Mellon Corp now owns 99,629 shares of the company’s stock worth $2,243,000 after buying an additional 17,195 shares during the period. Finally, PNC Financial Services Group Inc. raised its position in shares of Atara Biotherapeutics by 6,736.5% in the second quarter. PNC Financial Services Group Inc. now owns 6,563 shares of the company’s stock worth $148,000 after buying an additional 6,467 shares during the period. 75.50% of the stock is currently owned by institutional investors and hedge funds.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.